LN-229 Xenograft

The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987].

p53 + (mutated, CCT (Pro) --> CTT (Leu) mutation at codon 98), PTEN + (wild type), p16 - (deleted), p14ARF - (deleted)

Forms tumors in nude mice

Used in allogeneic xenografts

Receive a quote within one business day for a LN-229 xenograft

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA.

Because we specialize in tumor models, we're able to offer highly competitive prices.

Most efficacy studies can be initiated within two business days.

rincon bio